Innovative and adaptive strategies for new drug development are needed to maximize the potential of cell and gene therapies. CRA’s Lev Gerlovin, Walter Colasante, and Pascale Diesel explain in this Cell and Gene article. Click here to read the article.
Ken Beers joins CRA's Life Sciences Practice as Vice President
CRA is proud to welcome Kenneth J. Beers as a vice president in the Life Sciences Practice. Mr. Beers supports biopharmaceutical clients across a range of...